ID   Jiyoye
AC   CVCL_1317
SY   JIYOYE; Jijoye; JIJOYE; P-2003; P3 (Jiyoye); P-3-Jijoye; P3-Jiyoye; P-3J; P3J; Jiyoye(P-2003); Jiyoye (P-2003); JiyoyeP-2003; JIYOYEP2003; OB2; GM04678
DR   CLO; CLO_0007025
DR   CLO; CLO_0019011
DR   EFO; EFO_0002215
DR   CLDB; cl2945
DR   CLDB; cl2946
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CCL-87
DR   ATCC; CRL-7933
DR   BioGRID_ORCS_Cell_line; 270
DR   BioSample; SAMN01821570
DR   BioSample; SAMN01821640
DR   BioSample; SAMN03471289
DR   cancercelllines; CVCL_1317
DR   Cell_Model_Passport; SIDM00808
DR   ChEMBL-Cells; CHEMBL3307658
DR   ChEMBL-Targets; CHEMBL614588
DR   CLS; 300366
DR   Coriell; GM04678
DR   Cosmic; 687846
DR   Cosmic; 907268
DR   Cosmic; 931105
DR   Cosmic; 1818344
DR   Cosmic; 2822950
DR   Cosmic-CLP; 907268
DR   DepMap; ACH-002252
DR   DSMZ; ACC-590
DR   DSMZCellDive; ACC-590
DR   ECACC; 88071302
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 907268
DR   GEO; GSM1669960
DR   IARC_TP53; 702
DR   IGRhCellID; Jiyoye
DR   IZSLER; BS TCL 32
DR   KCLB; 10087
DR   LINCS_LDP; LCL-2021
DR   NCBI_Iran; C117
DR   PharmacoDB; Jiyoye_703_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1317
DR   PubChem_Cell_line; CVCL_1317
DR   Wikidata; Q54898929
RX   CelloPub=CLPUB00447;
RX   DOI=10.1007/BF02618370;
RX   PubMed=1915267;
RX   PubMed=2998993;
RX   PubMed=3026973;
RX   PubMed=3518877;
RX   PubMed=4169243;
RX   PubMed=4321017;
RX   PubMed=4321974;
RX   PubMed=4736620;
RX   PubMed=4894370;
RX   PubMed=5786183;
RX   PubMed=6018567;
RX   PubMed=6231253;
RX   PubMed=6500159;
RX   PubMed=7316467;
RX   PubMed=8108117;
RX   PubMed=8515068;
RX   PubMed=9473234;
RX   PubMed=17254797;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20454443;
RX   PubMed=25485619;
RX   PubMed=25787276;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: African; Nigerian.
CC   Virology: Contains a complete EBV genome (strain Jiyoye) which has been sequenced (PubMed=25787276).
CC   Doubling time: ~30-60 hours (DSMZ=ACC-590).
CC   HLA typing: A*03:01,74:01; B*53:01,58:01; C*04:01,04:01; DQA1*01:02,05:01; DQB1*03:01,06:02; DRB1*11:02,15:03 (PubMed=26589293).
CC   HLA typing: A*03:01:01,74:01:01; B*53:01:01,58:01:01; C*04:01:01; DPB1*01:01:01,02:01:02; DQA1*01:02:01,05:05:01; DQB1*03:19:01,06:02:01; DRB1*11:02:01,15:03:01 (CLS=300366).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Unspecified (PubMed=1915267).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=92.69%; Native American=0%; East Asian, North=2.15%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=5.16% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-7933; true.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; IZSLER; KCLB; PubMed=17254797
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 9,10 (PubMed=17254797)
ST   D16S539: 10,11 (ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; IZSLER; KCLB)
ST   D18S51: 12
ST   D19S433: 12,15
ST   D21S11: 27 (PubMed=17254797)
ST   D21S11: 28,36 (CLS; DSMZ; IZSLER)
ST   D2S1338: 21
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 8,10
ST   D8S1179: 14,15
ST   FGA: 23,24
ST   Penta D: 2.2,12 (CLS)
ST   Penta D: 3,12 (DSMZ)
ST   Penta E: 8,12
ST   TH01: 7,9
ST   TPOX: 6,8
ST   vWA: 15,19
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 44
//
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
//
RX   DOI=10.1007/BF02618370;
RA   Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.;
RT   "The animal cell culture collection.";
RL   In Vitro 5:1-16(1970).
//
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
//
RX   PubMed=2998993;
RA   Steel C.M., Morten J.E.N., Foster E.;
RT   "The cytogenetics of human B lymphoid malignancy: studies in Burkitt's
RT   lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell
RT   lines.";
RL   IARC Sci. Publ. 60:265-292(1985).
//
RX   PubMed=3026973; DOI=10.1002/ijc.2910390215;
RA   Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.;
RT   "Expression of B-cell-specific markers in different Burkitt lymphoma
RT   subgroups.";
RL   Int. J. Cancer 39:211-218(1987).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4169243; DOI=10.1093/jnci/39.5.1027;
RA   Klein G., Clifford P., Klein E., Smith R.T., Minowada J.,
RA   Kourilsky F.M., Burchenal J.H.;
RT   "Membrane immunofluorescence reactions of Burkitt lymphoma cells from
RT   biopsy specimens and tissue cultures.";
RL   J. Natl. Cancer Inst. 39:1027-1044(1967).
//
RX   PubMed=4321017; DOI=10.1002/ijc.2910060315;
RA   Durr F.E., Monroe J.H., Schmitter R., Traul K.A., Hirshaut Y.;
RT   "Studies on the infectivity and cytopathology of Epstein-Barr virus in
RT   human lymphoblastoid cells.";
RL   Int. J. Cancer 6:436-449(1970).
//
RX   PubMed=4321974;
RA   Maurer B.A., Imamura T., Wilbert S.M.;
RT   "Incidence of EB virus-containing cells in primary and secondary
RT   clones of several Burkitt lymphoma cell lines.";
RL   Cancer Res. 30:2870-2875(1970).
//
RX   PubMed=4736620; DOI=10.1111/j.1469-1809.1973.tb00588.x;
RA   Povey S., Gardiner S.E., Watson B., Mowbray S., Harris H., Arthur E.,
RA   Steel C.M., Blenkinsop C., Evans H.J.;
RT   "Genetic studies on human lymphoblastoid lines: isozyme analysis on
RT   cell lines from forty-one different individuals and on mutants
RT   produced following exposure to a chemical mutagen.";
RL   Ann. Hum. Genet. 36:247-266(1973).
//
RX   PubMed=4894370; DOI=10.1002/1097-0142(196908)24:2<211::AID-CNCR2820240202>3.0.CO;2-3;
RA   Southam C.M., Burchenal J.H., Clarkson B.D. Sr., Tanzi A., Mackey R.,
RA   McComb V.;
RT   "Heterotransplantability of human cell lines derived from leukemia and
RT   lymphomas into immunologically tolerant rats.";
RL   Cancer 24:211-222(1969).
//
RX   PubMed=5786183; DOI=10.1128/JVI.3.5.525-527.1969;
RA   McCormick K.J., Stenback W.A., Trentin J.J., Klein G., Nadkarni J.S.,
RA   Nadkarni J.J., Clifford P.;
RT   "Complement-fixation test for detection of herpes-like viruses in cell
RT   cultures of Burkitt's lymphoma.";
RL   J. Virol. 3:525-527(1969).
//
RX   PubMed=6018567;
RA   Miles C.P., O'Neill F.;
RT   "Chromosome studies of 8 in vitro lines of Burkitt's lymphoma.";
RL   Cancer Res. 27:392-402(1967).
//
RX   PubMed=6231253; DOI=10.1002/ijc.2910330407;
RA   Ehlin-Henriksson B., Klein G.;
RT   "Distinction between Burkitt lymphoma subgroups by monoclonal
RT   antibodies: relationships between antigen expression and type of
RT   chromosomal translocation.";
RL   Int. J. Cancer 33:459-463(1984).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x;
RA   Povey S., Jeremiah S., Arthur E., Steel M., Klein G.;
RT   "Differences in genetic stability between human cell lines from
RT   patients with and without lymphoreticular malignancy.";
RL   Ann. Hum. Genet. 44:119-133(1980).
//
RX   PubMed=8108117;
RA   Albert T., Urlbauer B., Kohlhuber F., Hammersen B., Eick D.;
RT   "Ongoing mutations in the N-terminal domain of c-Myc affect
RT   transactivation in Burkitt's lymphoma cell lines.";
RL   Oncogene 9:759-763(1994).
//
RX   PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
//
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
//
RX   PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001;
RA   Azari S., Ahmadi N., Tehrani M.J., Shokri F.;
RT   "Profiling and authentication of human cell lines using short tandem
RT   repeat (STR) loci: report from the National Cell Bank of Iran.";
RL   Biologicals 35:195-202(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25787276; DOI=10.1128/JVI.03614-14;
RA   Palser A.L., Grayson N.E., White R.E., Corton C., Correia S.,
RA   Ba Abdullah M.M., Watson S.J., Cotten M., Arrand J.R., Murray P.G.,
RA   Allday M.J., Rickinson A.B., Young L.S., Farrell P.J., Kellam P.;
RT   "Genome diversity of Epstein-Barr virus from multiple tumor types and
RT   normal infection.";
RL   J. Virol. 89:5222-5237(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//